Status:

COMPLETED

A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Lead Sponsor:

Eli Lilly and Company

Conditions:

Non Small Cell Lung Carcinoma

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study is a randomized Phase 3 study comparing pemetrexed and cisplatin combination to gemcitabine and cisplatin for the treatment of Non Small Cell Lung Cancer (NCSLC). Gemcitabine plus cisplatin...

Eligibility Criteria

Inclusion

  • Diagnosis of NSCLC Stage IIIB not amenable to curative treatment or Stage IV.
  • No prior chemotherapy for lung cancer.
  • Patients must have at least one uni-dimensionally measurable lesion.
  • Prior radiation therapy to less than 25% of bone marrow, whole pelvis not allowed. Radiation must be completed at least 4 weeks prior to study enrollment.

Exclusion

  • Treatment with any drug within the last 30 days that has not received regulatory approval.
  • Serious cardiac condition.
  • Serious medical disorder in addition to NSCLC that would make it difficult for the patient to complete the study.
  • Inability or unwillingness to take folic acid or Vitamin B12 supplementation.
  • Presence of fluid retention that cannot be controlled by drainage.

Key Trial Info

Start Date :

July 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2008

Estimated Enrollment :

1713 Patients enrolled

Trial Details

Trial ID

NCT00087711

Start Date

July 1 2004

End Date

March 1 2008

Last Update

September 12 2019

Active Locations (134)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 34 (134 locations)

1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Sacramento, California, United States

2

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Torrance, California, United States

3

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Jacksonville, Florida, United States

4

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Macon, Georgia, United States